Pharmia Bio Genesis Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 22-05-2024
- Paid Up Capital ₹ 2.00 M
as on 22-05-2024
- Company Age 14 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 11.67%
(FY 2017)
- Profit 14.90%
(FY 2017)
- Ebitda 210.79%
(FY 2017)
- Net Worth 10.17%
(FY 2017)
- Total Assets 3.50%
(FY 2017)
About Pharmia Bio Genesis
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M, as per Ministry of Corporate Affairs (MCA) records.
Rameshkumar Kizahaparambil, Vinod Manchakandy, Ramdas Thuppalle, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24234KA2010PTC052066
- Company No.
052066
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jan 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Pharmia Bio Genesis?
Executive Team (1)
RK
Rameshkumar Kizahaparambil
Managing DirectorAppointment Date: 04-Jan-2010
Status: Current
Board Members(5)
Financial Performance and Corporate Structure Insights of Pharmia Bio Genesis.
Pharmia Bio Genesis Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 11.67% increase. The company also saw a substantial improvement in profitability, with a 14.9% increase in profit. The company's net worth Soared by an impressive increase of 10.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pharmia Bio Genesis?
In 2017, Pharmia Bio Genesis had a promoter holding of 45.00% and a public holding of 55.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
North Malabar Chamber Of Commerce
Active
72 years 2 months Rameshkumar Kizahaparambil is a mutual person
Bangalore Pharma Formulations Private Limited
Active 18 years 7 months Rameshkumar Kizahaparambil is a mutual person
Kanhangad Links Private Limited
Active 3 years 4 months Rameshkumar Kizahaparambil is a mutual person
Emmar Drug Links Private Limited
Active 3 years 6 months Rameshkumar Kizahaparambil is a mutual person
Newniz Developers Private Limited
Active 12 years 16 days Rameshkumar Kizahaparambil is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Pharmia Bio Genesis?
Unlock and access historical data on people associated with Pharmia Bio Genesis, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Apr 29, 2014, Pharmia Bio Genesis has raised a total of ₹ 1.55 M, with the most recent deal valued at ₹ 0.3 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
